Riccardo Sarzani, Paolo Dessì-Fulgheri. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Angiotensin II Type 1 Receptor Blockers/administration & dosageAngiotensin II Type 1 Receptor Blockers/adverse effectsAngiotensin-Converting Enzyme Inhibitors/administration & dosageAngiotensin-Converting Enzyme Inhibitors/adverse effectsAntihypertensive Agents/administration & dosageAntihypertensive Agents/adverse effectsClinical Trials as TopicDose-Response Relationship, DrugHumansHypertension/complicationsHypertension/drug therapyMyocardial Infarction/etiologyMyocardial Infarction/prevention & controlResearch DesignTetrazoles/administration & dosageTetrazoles/adverse effectsValine/administration & dosageValine/adverse effectsValine/analogs & derivativesValsartan
Substances： See more » Angiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsTetrazolesValsartanValine
Year: 2006 PMID： 16877973 DOI： 10.1097/01.hjh.0000239307.86248.80
Source DB: PubMed Journal: J Hypertens ISSN： 0263-6352 Impact factor: 4.844